-79% of people treated for the first time achieved a SVR (viral cure) with INCIVEK combination treatment-
-Vertex launches a comprehensive financial assistance and patient support program-
-Conference call today at
INCIVEK (750 mg) is given as two 375-mg tablets three times daily for 12 weeks. It is packaged in weekly boxes that include daily blister strips to help patients keep track of their doses. (Photo: Business Wire)
The approval of INCIVEK was based on data from three Phase 3 studies, which showed that people who received INCIVEK combination treatment achieved significantly higher rates of sustained viral response (SVR, or viral cure) compared to those who received pegylated-interferon and ribavirin alone, regardless of their prior treatment experience:
People new to treatment:
79 percent vs. 46 percent
People who were treated previously but did not achieve a viral cure:
|86 percent vs. 22 percent|
-- Partial responders:
|59 percent vs. 15 percent|
-- Null responders:
|32 percent vs. 5 percent|
INCIVEK (750 mg) is given as two 375-mg tablets three times daily. It is packaged in weekly boxes that include daily blister strips to help patients keep track of their doses.
Rash and anemia are the most serious side effects associated with INCIVEK. The most common side effects reported with INCIVEK combination treatment include fatigue, itching, nausea, diarrhea, vomiting, anal or rectal problems, and taste changes.
"Hepatitis C can lead to liver failure, cancer and the need for a
transplant, and for the past decade, the best we could offer patients
was a year of difficult treatment that resulted in a viral cure for
fewer than half of them," said
"Today marks a turning point in the fight against hepatitis C,
particularly for people who have been living with this silent disease
for decades, hoping for a better chance of a viral cure," said
Vertex has 200 field-based employees across
Helping People with Hepatitis C Get INCIVEK
The people who work at Vertex understand that medicines can only help patients who can get them. With that in mind, the company today introduced a comprehensive financial assistance and patient support program to help people get INCIVEK who might not otherwise be able to afford it. The program will help people with hepatitis C learn about insurance benefits for their medicines, give INCIVEK for free to eligible patients who do not have insurance and provide coverage for co-pay or co-insurance costs associated with INCIVEK for people who meet certain program criteria. Additionally, patients will have access to nurses through a 24-7 hotline by which they can receive support, guidance and educational materials about hepatitis C and its treatment. Vertex will also provide nurses and doctors with educational tools and resources so they can offer support and care to people with hepatitis C before, during and after the treatment process.
For eligible patients, the program includes the following:
More information about this program is available by calling 1-855-837-8394 or visiting www.INCIVEK.com.
INCIVEK is an oral medicine that acts directly on the hepatitis C virus protease, an enzyme essential for viral replication. The Phase 3 registration studies evaluated INCIVEK in combination with Pegasys® (pegylated-interferon alfa-2a) and Copegus® (ribavirin) in people with hepatitis C who were new to treatment as well as those who were treated previously with pegylated-interferon and ribavirin but who did not achieve a viral cure, including:
Vertex developed telaprevir in collaboration with Tibotec BVBA and
INCIVEK™ (telaprevir) is a prescription medicine used with the medicines peginterferon alfa and ribavirin to treat chronic (lasting a long time) hepatitis C genotype 1 infection in adults with stable liver problems, who have not been treated before or who have failed previous treatment.
It is not known if INCIVEK is safe and effective in children under 18 years of age.
IMPORTANT SAFETY INFORMATION
Who should not take INCIVEK?
Do not take INCIVEK if you are pregnant or may become pregnant, or if you are a man with a sexual partner who is pregnant.
Do not take INCIVEK if you are taking certain medicines as there could
be serious side effects. If these drugs are taken together, this can
cause you to have too much or not enough INCIVEK or your other medicines
in your body. It can also cause side effects that can be serious or
life-threatening. These medicines include: alfuzosin hydrochloride
(Uroxatral®), atorvastatin (Lipitor®, Caduet®),
ergot containing medicines such as methylergonovine (Methergine®),
lovastatin (Advicor®, Altoprev®, Mevacor®),
pimozide (Orap®), rifampin (Rifadin®, Rifamate®,
Rifater®), sildenafil citrate (Revatio®) or
tadalafil (Adcirca®) for the lung problem pulmonary artery
hypertension (PAH), simvastatin (Zocor®, Vytorin®,
Talk to your healthcare provider before taking INCIVEK if any of the above applies to you. Your healthcare provider may need to change the amount of medicines you take.
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. INCIVEK and other medicines can affect each other.
Serious Side Effects
INCIVEK can cause serious side effects, including:
What should I tell my healthcare provider before taking INCIVEK?
Tell your healthcare provider if you:
How should I take INCIVEK?
Take INCIVEK exactly as your healthcare provider tells you. Take 2 INCIVEK pills 3 times a day, 7 to 9 hours apart, with food. Eat a meal or snack containing about 20 grams of fat within 30 minutes before you take each dose. Talk to your healthcare provider about examples of food you can eat.
If you miss a dose within 4 hours of when you usually take it, take your
dose with food as soon as possible. If you miss a dose and it is more
than 4 hours after the time you usually take it, skip that dose only and
take the next dose at your normal time. Do not stop taking INCIVEK
unless your healthcare provider tells you to. If your healthcare
provider tells you to stop, you should not start taking it again, even
if the reason for stopping goes away. If you take too much INCIVEK, call
your healthcare provider or local
Common Side Effects of INCIVEK Combination Treatment
The most common side effects include itching, nausea, diarrhea, vomiting, anal or rectal problems (including hemorrhoids, discomfort or burning around or near the anus, itching around or near the anus), taste changes, and tiredness. Tell your healthcare provider about any side effect that bothers you or doesn't go away.
These are not all the possible side effects of INCIVEK. For more information, ask your healthcare provider or pharmacist.
You are encouraged to report negative side effects of prescription drugs
You may also report side effects to
Please see full Prescribing Information for INCIVEK including the Medication Guide available at www.INCIVEK.com.
For healthcare providers who are interested in information about INCIVEK, you can also call 1-877-824-4281.
Conference Call Information
Vertex will host a conference call and webcast today, May, 23, 2011 at
INCIVEK™ is a trademark of
PEGASYS® and COPEGUS® are registered trademarks of Hoffmann-La Roche.
About Hepatitis C
Hepatitis C is a serious liver disease caused by the hepatitis C virus, which is spread through direct contact with the blood of infected people and ultimately affects the liver.1 Chronic hepatitis C can lead to serious and life-threatening liver problems, including liver damage, cirrhosis, liver failure or liver cancer.1 Though many people with hepatitis C may not experience symptoms, others may have symptoms such as fatigue, fever, jaundice and abdominal pain.1
Unlike HIV and hepatitis B virus, chronic hepatitis C is curable.2 However, approximately 60 percent of people do not achieve SVR,3,4,5 or viral cure,6 after treatment with 48 weeks of pegylated-interferon and ribavirin alone. If treatment is not successful and a person does not achieve a viral cure, they remain at an increased risk for progressive liver disease.7,8
More than 170 million people worldwide are chronically infected with
hepatitis C.6 In
Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives. Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, epilepsy and other life-threatening diseases.
Founded more than 20 years ago in
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, as defined in
the Private Securities Litigation Reform Act of 1995, as amended,
including statements regarding (i) Vertex's sales team being ready to
support the introduction of INCIVEK, (ii) Vertex's financial assistance
and patient support programs and its commitment to help people who might
not otherwise be able to afford INCIVEK receive it and (iii) the use of
INCIVEK as a treatment for people with genotype 1 chronic hepatitis C
virus infection. While the company believes the forward-looking
statements contained in this press release are accurate, there are a
number of factors that could cause actual events or results to differ
materially from those indicated by such forward-looking statements.
Those risks and uncertainties include, among other things, risks related
to the commercialization of INCIVEK and the other risks listed under
Risk Factors in Vertex's annual report and quarterly reports filed with
For more information and to view Vertex's press releases, please visit www.vrtx.com.
(VRTX - GEN)
2 Pearlman BL and
3 Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
4 Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
5 McHutchison JG, Lawitz EJ, Shiffman ML, et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.
6 Ghany MG, Strader DB, Thomas DL, Seeff, LB. Diagnosis, management and treatment of hepatitis C; An update. Hepatology. 2009;49 (4):1-40.
7 Morgan TR, Ghany MG, Kim HY, Snow KK, Lindsay K, Lok AS. Outcome of sustained virological responders and non-responders in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial. Hepatology. 2008;50(Suppl 4):357A (Abstract 115).
8 Veldt BJ, Heathcote J, Wedmeyer H. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Annals of Internal Medicine. 2007; 147: 677-684.
10 Pyenson B, Fitch K,
12 Davis GL, Alter MJ,
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6733469&lang=en
617-444-6992 or email@example.com
News Provided by Acquire Media